Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,412JPY
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
¥2,412
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,465,256
52-wk High
¥2,750
52-wk Low
¥2,078

Latest Key Developments (Source: Significant Developments)

Nektar Therapeutics and Daiichi Sankyo Europe sign European licensing agreement for onzeald experimental treatment for breast cancer and brain metastases
Wednesday, 1 Jun 2016 08:15am EDT 

Nektar Therapeutics Says Also Entitled To Significant Double : Nektar therapeutics says entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments . Digit royalties on net sales in europe . Plans to submit an maa filing in june 2016 seeking conditional approval from ema for use of onzeald .Nektar therapeutics and daiichi sankyo europe gmbh sign european licensing agreement for onzeald(tm) (etirinotecan pegol), an investigational drug candidate being developed to treat patients with advanced breast cancer and brain metastases.  Full Article

Daiichi Sankyo provides update on HER3-lung study of patritumab in non-small cell lung cancer
Tuesday, 31 May 2016 08:30am EDT 

Daiichi Sankyo Co Ltd <4568.T> : Provides update on HER3-lung study of patritumab in non-small cell lung cancer (NCLC) . Two-Part phase 3 HER3-lung study of patritumab will not proceed into second part . Independent data monitoring committee concluded that first part of study (Part A) did not meet pre-defined efficacy criteria . Phase 2 study evaluating patritumab in previously-untreated recurrent, metastatic head, neck cancer is ongoing, enrolling patients .Decision followed recommendation of an independent data monitoring committee.  Full Article

Nitto signs partnership agreement with Daiichi Sankyo
Tuesday, 10 May 2016 09:00am EDT 

Nitto Denko Corp <6988.T> : Signed a partnership agreement with Daiichi Sankyo company, ltd. . Nitto will provide exclusive rights to passport system for an undisclosed compound owned by daiichi sankyo . Financial terms were not disclosed. .Will support clinical development of candidate in united states..  Full Article

R&I affirms Daiichi Sankyo's rating at "AA" and announces stable outlook
Thursday, 26 Nov 2015 01:00am EST 

Daiichi Sankyo Co Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA".Rating outlook stable.  Full Article

Daiichi Sankyo Co Ltd says will cut 1,000-1,200 jobs in U.S. - Reuters
Sunday, 18 Oct 2015 08:00pm EDT 

Daiichi Sankyo Co Ltd:The pharmaceutical company says it expects to cut 1,000-1,200 jobs in the United States - Reuters.Says will reorganise U.S. commercial organisation as it transitions from primary care product portfolio to differentiated specialty portfolio - Reuters.  Full Article

Daiichi Sankyo Co Ltd reorganizes its U.S. commercial operations to support upcoming specialty pipeline
Friday, 16 Oct 2015 11:11am EDT 

Daiichi Sankyo Co Ltd <4568.T>:Daiichi sankyo, inc. reorganizes its U.S. commercial operations to support upcoming specialty pipeline.Says company will reduce expenses, including a reduction in headcount, from its U.S. commercial operations.Says company expects to eliminate 1,000 to 1,200 positions across the U.S. commercial function.Says reorganization is not focused on U.S.-based research and development functions.Daiichi sankyo co - as part of reorganization, co will reduce expenses, including a reduction in headcount, from its U.S. commercial operations.Daiichi sankyo co -eliminated jobs will come from U.S. commercial home office, in Parsippany, new jersey,sales,other positions throughout country.To reorganize U.S. commercial organization as it transitions from primary care product portfolio to differentiated specialty portfolio.  Full Article

Daiichi Sankyo completes share repurchase
Tuesday, 25 Aug 2015 07:30pm EDT 

Daiichi Sankyo Co Ltd:Completes repurchase of 20,650,900 shares of its common stock, at the price of 49,999,930,971 yen in total, on Aug. 25.  Full Article

Daiichi Sankyo issues mid-year and year-end dividend forecasts for FY 2016
Thursday, 14 May 2015 12:00am EDT 

Daiichi Sankyo Co Ltd:Issues mid-year dividend forecast of 40 yen per share, for FY ending March 2016.Issues year-end dividend forecast of 30 yen per share, for FY ending March 2016.  Full Article

Daiichi Sankyo to repurchase shares
Thursday, 14 May 2015 12:00am EDT 

Daiichi Sankyo Co Ltd:To repurchase up to 28,000,000 shares, representing a 3.98 pct stake.Says share repurchase up to May 15 to Aug. 31.  Full Article

Daiichi Sankyo raises consolidated full-year outlook for FY 2015
Tuesday, 28 Apr 2015 02:30am EDT 

Daiichi Sankyo Co Ltd:Says the company increased the consolidated full-year outlook for revenue to 919,000 million yen from 900,000 million yen for FY ended March 2015.Sees a decrease of operating profit forecast to 74,000 million yen from 100,000 million yen.Sees a decrease of profit before tax forecast to 79,000 million yen from 100,000 million yen.Sees a decrease of net profit attributable to parent company's shareholders forecast to 46,000 million yen from 65,000 million yen.Sees a decrease of earnings per share to 65.34 yen from 92.33 yen.FY 2015 revenues of 936.03 billion yen, net income of 71.77 billion yen – Thomson Reuters I/B/E/S.Comments the sales increase and impairment loss of subsidiary Plexxikon Inc are the main reasons for the forecast.  Full Article

BRIEF-Portola Pharmaceuticals expands pact with Daiichi Sankyo

* Portola Pharmaceuticals expands clinical collaboration agreement with Daiichi Sankyo worth up to $25 million to develop ANDEXXA (Andexanet Alfa) in Germany